<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression</title>
<style>
body { font-family: Arial, Helvetica, sans-serif; background:#0f1115; color:#e6e6e6; margin:0; padding:40px; }
.container { max-width:700px; margin:auto; background:#161a21; border-radius:10px; padding:32px; box-shadow:0 0 30px rgba(0,0,0,0.4); }
h1 { margin-top:0; color:#4da3ff; }
table { width:100%; margin-top:12px; border-collapse:collapse; }
th, td { text-align:left; padding:6px 8px; border-bottom:1px solid #2a2f3a; }
ul { margin-top:12px; padding-left:20px; }
.section { margin-top:24px; }
.small { margin-top:12px; font-size:13px; color:#999; }
a { color:#4da3ff; }
</style>
</head>
<body>
  <div class="container">
    <h1>Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression</h1>

    <table>
      <tr><th>Ticker</th><td>CMPS</td></tr>
      <tr><th>Float</th><td>94.2 M</td></tr>
      <tr><th>IO</th><td>57.92%</td></tr>
      <tr><th>MC</th><td>558 M</td></tr>
      <tr><th>Extra Info</th><td>None</td></tr>
    </table>

    <div class="section">
      <strong>Summary</strong>
      <p>Press release: Compass Pathways (CMPS) announced that COMP360 psilocybin met the primary endpoint in a second Phase 3 clinical trial for treatment-resistant depression (TRD). The company reported the trial achieved its prespecified primary efficacy outcome; no additional trial metrics, safety details, or regulatory next steps were provided in the supplied text.</p>
    </div>

    <div class="section">
      <strong>Positives</strong>
      <ul><li>COMP360 met the primary endpoint in a second Phase 3 trial for treatment-resistant depression</li></ul>
    </div>

    <div class="section">
      <strong>Negatives</strong>
      <ul><li>None</li></ul>
    </div>

    <div class="section">
      <a href="https://news.nuntiobot.com/article/49caf4d8-8464-4d58-b3f0-9e2de27439d3" target="_blank">Original Article</a>
    </div>

    <div class="small">CMPS â€¢ TradersLink AI News</div>
  </div>
</body>
</html>